Evidence map›Paper›PMID 40206078›Full record

ArticleFrontiers in pharmacology2025

A phase I study to evaluate the safety, tolerability, and pharmacokinetics of HEC113995PA·H

Xue Wu, Qingqing Wu, Qichen Ding, Yulei Zhuang, Lin Luo, Yingjun Zhang, Li Deng, Chuanfei Jin, Xue Li, Zhangma Huang and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Xue WuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital, Shanghai, China.
Qingqing WuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital, Shanghai, China.
Qichen DingDrug Clinical Trial Center, Shanghai Xuhui Central Hospital, Shanghai, China.
Yulei ZhuangSunshine Lake Pharma Co., LTD., Guangdong, China.
Lin LuoSunshine Lake Pharma Co., LTD., Guangdong, China.
Yingjun ZhangSunshine Lake Pharma Co., LTD., Guangdong, China.
Li DengSunshine Lake Pharma Co., LTD., Guangdong, China.
Chuanfei JinSunshine Lake Pharma Co., LTD., Guangdong, China.
Xue LiSunshine Lake Pharma Co., LTD., Guangdong, China.
Zhangma HuangSunshine Lake Pharma Co., LTD., Guangdong, China.
Haiping QinED (Emergency Department) Emergency Ward, Shanghai Xuhui Central Hospital, Shanghai, China.
Liang XinDrug Clinical Trial Center, Shanghai Xuhui Central Hospital, Shanghai, China.
Qian ChenDrug Clinical Trial Center, Shanghai Xuhui Central Hospital, Shanghai, China.
Jingying JiaDrug Clinical Trial Center, Shanghai Xuhui Central Hospital, Shanghai, China.
Yanmei LiuDrug Clinical Trial Center, Shanghai Xuhui Central Hospital, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: HEC113995PA·H Methods: The entire study was comprised of three parts: Part I (single ascending-dose study), Part II (food effect study), and Part III (multiple ascending-dose study). A total of 121 healthy subjects were enrolled in the study. HEC113995PA·H Results: In Part I, AUC and C Conclusion: HEC113995PA·H

Indexed as

food effectH2Ohealthy subjectsHEC113995PApharmacokineticssafetySPARI

Identifiers

PMID40206078
PMCPMC11979273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.